These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27609113)

  • 21. Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
    Low CL; Gopalakrishna K; Lye WC
    J Am Soc Nephrol; 2000 Jun; 11(6):1117-1121. PubMed ID: 10820176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares.
    Donecker JM; Sams RA; Ashcraft SM
    Am J Vet Res; 1986 Jan; 47(1):89-95. PubMed ID: 3946913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Data averaging in pharmacokinetic analysis: the population pharmacokinetics of cephalothin and cefazolin].
    Firsov AA; Danilova VI; Geodakian SV
    Antibiot Med Biotekhnol; 1987 Jul; 32(7):502-8. PubMed ID: 3118794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.
    Brill MJ; Houwink AP; Schmidt S; Van Dongen EP; Hazebroek EJ; van Ramshorst B; Deneer VH; Mouton JW; Knibbe CA
    J Antimicrob Chemother; 2014 Mar; 69(3):715-23. PubMed ID: 24214905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Free and total cefazolin plasma and interstitial fluid concentrations at steady state during continuous infusion.
    Howard GW; Begg EJ; Chambers ST; Vella Brincat J; Zhang M; Kirkpatrick CM
    J Antimicrob Chemother; 2002 Sep; 50(3):429-32. PubMed ID: 12205071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery.
    Young OM; Shaik IH; Twedt R; Binstock A; Althouse AD; Venkataramanan R; Simhan HN; Wiesenfeld HC; Caritis SN
    Am J Obstet Gynecol; 2015 Oct; 213(4):541.e1-7. PubMed ID: 26103528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients.
    van Kralingen S; Taks M; Diepstraten J; van de Garde EM; van Dongen EP; Wiezer MJ; van Ramshorst B; Vlaminckx B; Deneer VH; Knibbe CA
    Eur J Clin Pharmacol; 2011 Oct; 67(10):985-92. PubMed ID: 21499760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and bone tissue concentrations of lincomycin following intravenous and intramuscular administrations to cats.
    Albarellos GA; Montoya L; Denamiel GA; Velo MC; Landoni MF
    J Vet Pharmacol Ther; 2012 Dec; 35(6):534-40. PubMed ID: 22132730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery.
    Douglas A; Udy AA; Wallis SC; Jarrett P; Stuart J; Lassig-Smith M; Deans R; Roberts MS; Taraporewalla K; Jenkins J; Medley G; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5238-42. PubMed ID: 21859939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of meropenem after intravenous, intramuscular and subcutaneous administration to cats.
    Albarellos GA; Montoya L; Passini SM; Lupi MP; Lorenzini PM; Landoni MF
    J Feline Med Surg; 2016 Dec; 18(12):976-980. PubMed ID: 26347549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of intravenous and oral methimazole following single- and multiple-dose administration in normal cats.
    Trepanier LA; Peterson ME; Aucoin DP
    J Vet Pharmacol Ther; 1991 Dec; 14(4):367-73. PubMed ID: 1774813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin (author's transl)].
    Adam D; Pätzold J
    Infection; 1977; 5(4):228-31. PubMed ID: 598929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of minocycline in domestic cats.
    Tynan BE; Papich MG; Kerl ME; Cohn LA
    J Feline Med Surg; 2016 Apr; 18(4):257-63. PubMed ID: 25851119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years.
    Schmitz ML; Blumer JL; Cetnarowski W; Rubino CM
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4173-80. PubMed ID: 25941220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section?
    Kram JJF; Greer DM; Cabrera O; Burlage R; Forgie MM; Siddiqui DS
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():334-341. PubMed ID: 28122314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefazolin dosing for surgical prophylaxis in morbidly obese patients.
    Ho VP; Nicolau DP; Dakin GF; Pomp A; Rich BS; Towe CW; Barie PS
    Surg Infect (Larchmt); 2012 Feb; 13(1):33-7. PubMed ID: 22316145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats.
    King JN; Jung M; Maurer MP; Schmid VB; Seewald W; Lees P
    Am J Vet Res; 2013 Mar; 74(3):465-72. PubMed ID: 23438125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters.
    Adembri C; Ristori R; Chelazzi C; Arrigucci S; Cassetta MI; De Gaudio AR; Novelli A
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):471-5. PubMed ID: 20570290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats.
    Albarellos GA; Ambros LA; Landoni MF
    J Vet Pharmacol Ther; 2005 Aug; 28(4):363-9. PubMed ID: 16050816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.